Industry
Biotechnology
60 Degrees Pharmaceuticals, Inc. operates as a specialty pharmaceutical company that engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19; Tafenoquine for fungal lung infections, tick-borne diseases, candidiasis, and other infectious and non-infectious diseases; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is based in Washington, District of Columbia.
Loading...
Open
0.95
Mkt cap
2.1M
Volume
32K
High
0.95
P/E Ratio
-0.09
52-wk high
18.36
Low
0.86
Div yield
N/A
52-wk low
0.70
Portfolio Pulse from Benzinga Newsdesk
October 20, 2023 | 11:15 am
Portfolio Pulse from Benzinga Insights
October 19, 2023 | 1:06 pm
Portfolio Pulse from Happy Mohamed
October 19, 2023 | 12:42 pm
Portfolio Pulse from Benzinga Insights
October 12, 2023 | 9:32 pm
Portfolio Pulse from Benzinga Newsdesk
October 12, 2023 | 8:18 pm
Portfolio Pulse from Benzinga Insights
October 04, 2023 | 9:31 pm
Portfolio Pulse from Benzinga Newsdesk
October 02, 2023 | 10:22 am
Portfolio Pulse from Lisa Levin
September 19, 2023 | 6:32 pm
Portfolio Pulse from Benzinga Insights
September 19, 2023 | 1:06 pm
Portfolio Pulse from Vandana Singh
September 19, 2023 | 1:04 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.